OncLive TV

Hearn Jay Cho, MD, PhD, associate professor of medicine, Hematology/Oncology, Icahn School of Medicine, Mount Sinai Hospital, discusses ongoing research with checkpoint inhibitors in multiple myeloma.

Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses improving methods of diagnosis for women with uterine leiomyosarcoma.

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the plethora of new treatment options in hepatocellular carcinoma.

David M. Siegel, MD, PhD, chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.

Nina Shah, MD, associate professor of medicine at the University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the potential of bb21217 in the treatment of patients with multiple myeloma.

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

Krish Patel, MD, oncologist, Swedish Cancer Institute, discusses differences between BTK inhibitors in mantle cell lymphoma (MCL).

Huma Q. Rana, MD, clinical director, Cancer Genetics and Prevention, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses genetic testing guidelines for patients with ovarian cancer.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses unmet needs in endometrial and cervical cancers.

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses updated findings from the DUO study in patients with chronic lymphocytic leukemia.

Joshua K. Sabari, MD, assistant professor of medicine, NYU Langone's Perlmutter Cancer Center, discusses biomarkers of immunotherapy response in non–small cell lung cancer.

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses the standard of care for transplant eligible patients with multiple myeloma.

Joyce F. Liu, MD, MPH, assistant professor of medicine and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of bevacizumab (Avastin) in the treatment of patients with newly diagnosed advanced ovarian cancer.

Bradley G. Somer, MD, an associate professor of hematology/oncology and head of strategic expansion/development at the University of Tennessee West Cancer Center, discusses treatment selection considerations in renal cell carcinoma (RCC).

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the safety and efficacy of single-agent acalabrutinib in the treatment of mantle cell lymphoma.

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the impact of T-DM1 in HER2-positive breast cancer.

Roman Perez-Soler, MD, chairman of the Department of Oncology and chief of the Division of Medical Oncology at Montefiore Medical Center, discusses recent advances in immunotherapy for the treatment of patients with small cell lung cancer.

John Strickler, MD, assistant professor of medicine, Duke University School of Medicine, gastrointestinal oncologist, Duke Cancer Institute, discusses the value of liquid biopsies in the treatment of patients with colorectal cancer (CRC).

Alexander Drilon, MD, medical oncologist, clinical director, Early Drug Development Service, Memorial Sloan Kettering Cancer Center, discusses emerging biomarkers in non–small cell lung cancer (NSCLC).

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the role of cemiplimab in the treatment of patients with cervical cancer.

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

Joaquim Bellmunt, MD, PhD, genitourinary oncologist, Beth Israel Deaconess Medical Center, associate professor of medicine, Harvard Medical School, differentiates between immunotherapy options available for the treatment of patients with in bladder cancer.

Samir Parekh, MD, associate professor of Medicine, Mount Sinai Health System, discusses the mechanism of action of selinexor in multiple myeloma.

Robert Dean, MD, staff physician, Cleveland Clinic, discusses FDA approved drugs for patients with relapsed mantle cell lymphoma.

Neeraj Agarwal, MD, associate professor, Division of Oncology, Department of Medicine, University of Utah School of Medicine, Huntsman Cancer Institute, discusses second-line therapy selection in metastatic renal cell carcinoma.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, and 2018 Giant of Cancer Care for Gynecological Cancers, discusses the treatment of ovarian cancer as a chronic disease.

Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the role of TKIs in the treatment of HER2-positive breast cancer.

Chris Parker, MD, consultant clinical oncologist, The Royal Marsden NHS Foundation Trust, discusses the role of radiotherapy in patients with metastatic prostate cancer.

Michael A. Choti, MD, chief of surgery, Banner MD Anderson Cancer Center, discusses the role of surgery in the treatment of patients with pancreatic cancer.